Pimobendan Inhibits HBV Transcription and Replication by Suppressing HBV Promoters Activity

Current anti-HBV therapeutic strategy relies on interferon and nucleos(t)ide-type drugs with the limitation of functional cure, inducing hepatitis B surface antigen (HBsAg) loss in very few patients. Notably, the level of HBsAg has been established as an accurate indicator to evaluate the drug effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Si-Yu, Yu, Hai-Bo, Yang, Zhen, Qin, Yi-Ping, Ren, Ji-Hua, Cheng, Sheng-Tao, Ren, Fang, Law, Betty Yuen Kwan, Wong, Vincent Kam Wai, Ng, Jerome P. L., Zhou, Yu-Jiao, He, Xin, Tan, Ming, Zhang, Zhen-Zhen, Chen, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204083/
https://www.ncbi.nlm.nih.gov/pubmed/35721154
http://dx.doi.org/10.3389/fphar.2022.837115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204083/
https://www.ncbi.nlm.nih.gov/pubmed/35721154
http://dx.doi.org/10.3389/fphar.2022.837115

Ejemplares similares